<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01639664</url>
  </required_header>
  <id_info>
    <org_study_id>6233</org_study_id>
    <nct_id>NCT01639664</nct_id>
  </id_info>
  <brief_title>COMPACT 2 - COMbining Plasma-filtration and Adsorption Clinical Trial 2</brief_title>
  <acronym>COMPACT-2</acronym>
  <official_title>COMPACT (COMbining Plasma-filtration and Adsorption Clinical Trial): Efficacy and Safety of High Doses CPFA (Coupled Plasma Filtration Adsorption) for Septic Shock in the ICU</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BELLCO Srl Mirandola (MO) ITALY</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objective is to clarify whether the application of high doses CPFA (coupled&#xD;
      plasma-filtration adsorption) in addition to the current clinical practice is able to reduce&#xD;
      hospital mortality in septic shock patients in intensive care unit (ICU).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Septic shock is a life-threatening clinical condition characterized by cardiovascular failure&#xD;
      as a consequence of infection. Septic shock frequently causes multi-organ failure in the ICU.&#xD;
      For this reason the extracorporeal therapies for the treatment of renal failure have become&#xD;
      widespread in the ICU and, at the same time, new extracorporeal depurative techniques have&#xD;
      been developed for the removal of inflammatory mediators. One of these techniques is CPFA&#xD;
      (coupled plasma-filtration adsorption) that uses a sorbent once the separation between plasma&#xD;
      and blood has been obtained with a plasma filter. The study objective is to clarify whether&#xD;
      the application of high doses CPFA in addition to the current clinical practice is able to&#xD;
      reduce hospital mortality in septic shock patients in intensive care unit. Secondary&#xD;
      objectives are the resolution of septic shock and the reduction of ICU LOS (length of stay).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The interim analysis requested by the EDSMC shows higher mortality for the CPFA group compared&#xD;
    to the controls, particularly in the first days of treatment.&#xD;
  </why_stopped>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">October 23, 2017</completion_date>
  <primary_completion_date type="Actual">October 23, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hospital Mortality</measure>
    <time_frame>At the discharge from the latest hospital (on average 30.3 days)</time_frame>
    <description>For patients discharged to other hospital, it will be intended as mortality at the discharge from the latest hospital in which the patients stayed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality Within 90 Days From Randomization</measure>
    <time_frame>90 days from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU LOS Reduction Measured as Days Not Spent in the ICU During the First 30 Days From Randomization</measure>
    <time_frame>30 days from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Septic Shock Resolution Measured as Number of Days Free of Vasoactive Drugs From Randomization</measure>
    <time_frame>15 days from randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">115</enrollment>
  <condition>Shock, Septic</condition>
  <arm_group>
    <arm_group_label>High doses CPFA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High doses CPFA (coupled plasma-filtration adsorption) with AMPLYA™ (BELLCO ITALY): &gt;0.20 L/kg/day of plasma treated in the first 3 days after randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>standard practice</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High doses CPFA</intervention_name>
    <description>High doses CPFA (coupled plasma-filtration adsorption) with AMPLYA™ (BELLCO ITALY): &gt;0.20 L/kg/day of plasma treated in the first 3 days after randomization.</description>
    <arm_group_label>High doses CPFA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients admitted to the ICU in septic shock&#xD;
&#xD;
          -  All patients that develop septic shock while in the ICU&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age less than 14 years&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Estimated life expectancy (due to comorbidities) less than 90 days&#xD;
&#xD;
          -  Presence of relative or absolute contraindications to CPFA&#xD;
&#xD;
          -  Admission from an other ICU where the patient remained for more than 24 hours&#xD;
&#xD;
          -  Absence of informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergio Livigni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale San Giovanni Bosco, Torino, ITALY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ospedale Madonna delle Grazie, U.O. di Anestesia e Rianimazione</name>
      <address>
        <city>Matera</city>
        <state>Basilicata</state>
        <zip>75100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Maurizio Bufalini, UO Anestesia Terapia Intensiva</name>
      <address>
        <city>Cesena</city>
        <state>Emilia Romagna</state>
        <zip>47023</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Morgagni-Pierantoni, U.O. Anestesia e Rianimazione</name>
      <address>
        <city>Forlì</city>
        <state>Emilia Romagna</state>
        <zip>47100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale A. Manzoni, U.O. Anestesia e Rianimazione 1</name>
      <address>
        <city>Lecco</city>
        <state>Lombardia</state>
        <zip>23900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale SS. Antonio e Biagio e C. Arrigo, Servizio Anestesia, Rianimazione e Terapia Antalgica</name>
      <address>
        <city>Alessandria</city>
        <state>Piemonte</state>
        <zip>15100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore</name>
      <address>
        <city>Chieri</city>
        <state>Piemonte</state>
        <zip>10023</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Croce</name>
      <address>
        <city>Moncalieri</city>
        <state>Piemonte</state>
        <zip>10027</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CTO Maria Adelaide, I Servizio Anestesia e Rianimazione</name>
      <address>
        <city>Torino</city>
        <state>Piemonte</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giovanni Bosco, Servizio Anestesia e Rianimazione B-DEA</name>
      <address>
        <city>Torino</city>
        <state>Piemonte</state>
        <zip>10148</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Careggi</name>
      <address>
        <city>Firenze</city>
        <state>Toscana</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti Valdichiana Senese, U.O. di Anestesia e Rianimazione</name>
      <address>
        <city>Montepulciano</city>
        <state>Toscana</state>
        <zip>53045</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale SS. Cosma e Damiano, Servizio Anestesia e Rianimazione</name>
      <address>
        <city>Pescia</city>
        <state>Toscana</state>
        <zip>51017</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Alta Val d'Elsa, Terapia Intensiva</name>
      <address>
        <city>Poggibonsi</city>
        <state>Toscana</state>
        <zip>53036</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.giviti.marionegri.it</url>
    <description>GiViTI web site</description>
  </link>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>July 6, 2012</study_first_submitted>
  <study_first_submitted_qc>July 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2012</study_first_posted>
  <results_first_submitted>January 15, 2021</results_first_submitted>
  <results_first_submitted_qc>September 2, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 5, 2021</results_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>septic shock</keyword>
  <keyword>intensive care medicine</keyword>
  <keyword>coupled plasma filtration-adsorption</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 4, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT01639664/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The interim analysis requested by the EDSMC shows higher mortality for the CPFA group compared to the controls, particularly in the first days of treatment. This result raise concern that the use of CPFA may cause harm or worsen the clinical condition of septic shock patients. For this reason we did not conclude the participant enrollment of the study.&#xD;
The COMPACT-2 study has been prematurely terminated as from 23/10/2017.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>High Doses CPFA</title>
          <description>High doses CPFA (coupled plasma-filtration adsorption) with AMPLYA™ (BELLCO ITALY): &gt;0.20 L/kg/day of plasma treated in the first 3 days after randomization and on each of the subsequent days in which the patient is still in septic-shock condition.</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>standard practice</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>High Doses CPFA</title>
          <description>High doses CPFA (coupled plasma-filtration adsorption) with AMPLYA™ (BELLCO ITALY): &gt;0.20 L/kg/day of plasma treated in the first 3 days after randomization.</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>Standard practice</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="63"/>
            <count group_id="B2" value="52"/>
            <count group_id="B3" value="115"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="63"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="115"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="63"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="115"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.9" spread="13.8"/>
                    <measurement group_id="B2" value="67.0" spread="10.5"/>
                    <measurement group_id="B3" value="67.0" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="63"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="115"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="63"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="115"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Length of stay before ICU admission</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="63"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="115"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.0" spread="7.2"/>
                    <measurement group_id="B2" value="3.0" spread="5.2"/>
                    <measurement group_id="B3" value="3.6" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SAPS II</title>
          <description>The Simplified Acute Physiology Score (SAPS II) is a severity score and mortality estimation tool developed from a large sample of medical and surgical patients in North America and Europe. SAPS II consists of 17 variables: 12 physiological variables, age, type of admission, and 3 variables related to underlying disease. For the physiological variables, the worst value during the first 24 hours of ICU admission is used for the calculation. The SAPS II results in a point score between 0 and 163 and a predicted mortality between 0% and 100%. Lower values are associated with lower mortality.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="63"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="115"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="45" upper_limit="73.8"/>
                    <measurement group_id="B2" value="55" lower_limit="47.8" upper_limit="67.5"/>
                    <measurement group_id="B3" value="57.5" lower_limit="46.75" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Septic shock on admission</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="63"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="115"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hospital Mortality</title>
        <description>For patients discharged to other hospital, it will be intended as mortality at the discharge from the latest hospital in which the patients stayed.</description>
        <time_frame>At the discharge from the latest hospital (on average 30.3 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Doses CPFA</title>
            <description>High doses CPFA (coupled plasma-filtration adsorption) with AMPLYA™ (BELLCO ITALY): &gt;0.20 L/kg/day of plasma treated in the first 3 days after randomization.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Standard practice</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Mortality</title>
          <description>For patients discharged to other hospital, it will be intended as mortality at the discharge from the latest hospital in which the patients stayed.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality Within 90 Days From Randomization</title>
        <time_frame>90 days from randomization</time_frame>
        <population>11 patients lost at the follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>High Doses CPFA</title>
            <description>High doses CPFA (coupled plasma-filtration adsorption) with AMPLYA™ (BELLCO ITALY): &gt;0.20 L/kg/day of plasma treated in the first 3 days after randomization.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Standard practice</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality Within 90 Days From Randomization</title>
          <population>11 patients lost at the follow-up</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ICU LOS Reduction Measured as Days Not Spent in the ICU During the First 30 Days From Randomization</title>
        <time_frame>30 days from randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Doses CPFA</title>
            <description>High doses CPFA (coupled plasma-filtration adsorption) with AMPLYA™ (BELLCO ITALY): &gt;0.20 L/kg/day of plasma treated in the first 3 days after randomization.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Standard practice</description>
          </group>
        </group_list>
        <measure>
          <title>ICU LOS Reduction Measured as Days Not Spent in the ICU During the First 30 Days From Randomization</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="9.7"/>
                    <measurement group_id="O2" value="9.3" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Septic Shock Resolution Measured as Number of Days Free of Vasoactive Drugs From Randomization</title>
        <time_frame>15 days from randomization</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All patients showing a serious adverse event probably related to the experimental technique were monitored until the symptoms disappear, or the laboratory values return to normal, or until a reasonable explanation of the observed changes emerges, or until death. In the last case, the pathologist report should be provided, whenever possible. Patients were monitored up to 90 days. All adverse events were recorded on an ad hoc form.</time_frame>
      <desc>In the field of intensive care medicine, the incidence of critical events during the stay in the ICU is high by definition. For this reason, only unfavorable and unintended sign (including abnormal laboratory finding), symptom, or disease probably related to the experimental technique has been taken into account. Non-treatment-related Adverse Events were not monitored.</desc>
      <group_list>
        <group group_id="E1">
          <title>High Doses CPFA</title>
          <description>High doses CPFA (coupled plasma-filtration adsorption) with AMPLYA™ (BELLCO ITALY): &gt;0.20 L/kg/day of plasma treated in the first 3 days after randomization.&#xD;
High doses CPFA: High doses CPFA (coupled plasma-filtration adsorption) with AMPLYA™ (BELLCO ITALY): &gt;0.20 L/kg/day of plasma treated in the first 3 days after randomization.</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>standard practice</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Guido Bertolini</name_or_title>
      <organization>Istituto di Ricerche Farmacologiche Mario Negri IRCCS</organization>
      <phone>035 4535 313</phone>
      <email>guido.bertolini@marionegri.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

